Positive immunohistochemical (IHC) expression of PD-L1 proved to be a predictive biomarker of efficacy in several solid tumors, including NSCLC, urothelial cancer (5), and HNSCC (6). Here, CD274 is linked to non-small cell lung carcinoma.